IBA - Second supply agreement secured by PanTera
PanTera signed a 2nd agreement for the supply of Act-225 – after the one with Bayer – with an undisclosed partner. Management highlights that this is an important contract representing 15-20% of the yearly volumes PanTera will be producing based on the TerraPower production route.This new contract further demonstrates the reliability and credibility of PanTera as Act-225 supplier. It currently only covers the supply for clinical trial needs but we could envision it to be upgraded to a commercial deal down the line.Remember that news on the Act-225 project is one of the 5 main drivers we see for theIBA- Ion Beam Applications develops and markets technologies and pharmaceutical products for the healthcare sector, with a focus on cancer diagnosis and therapy. Co. is also engaged in the sterilization and ionization market. Co. operates in two primary business segments: Equipment and Pharmaceuticals. Co.'s Equipment segment encompasses development, fabrication, and services associated with medical and industrial particle accelerators, proton therapy systems, and a range of dosimetry products, while Co.'s Pharmaceuticals segment encompasses the production and distribution of radiopharmaceutical agents as well as its bioassay operations.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.